Raltitrexed and the treatment of advanced colorectal cancer

Journal of Oncology Pharmacy Practice

Volumn 2, Issue 4, 1996, Pages 225-235

  Summerhayes, Maxwell ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

5 fluorouracil; Chemotherapy; Colorectal cancer; Folinate; Raltitrexed

Indexed keywords

EID: 0001643605     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/107815529600200404     Document Type: Article

References (88)

1. Cohen AM, Minsky BD, Schilsky RL Colon cancer. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: JB Lippincott; 1993:929-977.
2. Souhami R., Tobias J. Tumours of the small and large bowel. In: Cancer and its Management, 2nd ed. Oxford: Blackwell Science; 1995:305-316.
3. Willett WC, Stampfer MJ, Colditz GA,et al.Relation of meat, fat and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med. 1990;323:1664-1672.
4. Modan B. Diet and cancer: an overview. N Engl J Med. 1984;310:697-703.
5. Haenszel W., Correa P. Cancer of the colon and rectum and adenomatous polyps. A review of epidemiological findings. Cancer. 1971;28:14-24.
6. Anonymous. Is chemoprotection an option in colorectal cancer? Pharm J. 1995;254:33.
7. Dukes CE The classification of cancer of the rectum. J Pathol. 1932;35:323-332.
8. Moertel CG, Reitemeier RJ Chemotherapy of advanced gastrointestinal cancer: introduction. In: Moertel CJ, ed. Advanced Gastrointestinal Cancer: Clinical Management and Chemotherapy. New York: Harper and Row; 1969:73-76.
9. Poon MA, O'Connell MJ, Moertel CG,et al.Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989;7:1407-1418.
10. Poon MA, O'Connell MJ, Wieand HS,et al.Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol. 1991;9:1967-1992.
11. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896-903.
12. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol. 1992;10: 904-911.
13. Scheithauer W., Rosen H., Kornek G-V.,et al.Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752-755.
14. Allen-Mersh TG, Earlam S., Fordy C.,et al.Quality of life and survival with continuous hepatic artery infusion for colorectal liver metastases. Lancet. 1994;344:1255-1260.
15. Glimelius B., Hoffman K., Graf W.,et al.Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer. 1994;73:556-562.
16. Glimelius B., Hoffman K., Graf W.,et al.Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995;6:267-274.
17. Laurie JA, Moertel CG, Fleming TR,et al.Surgical adjuvant therapy of large-bowel carcinoma. An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol. 1989;7:1447-1456.
18. Moertel CG, Fleming TR, Macdonald JS,et al.Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322: 352-358.
19. Moertel CG, Fleming TR, Macdonald JS,et al.Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-326.
20. The IMPACT investigators group. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet. 1995;345:939 -944.
21. Grage TB, Moss SE Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of the effectiveness of plrolonged 5-FU chemotherapy in a prospectively randomized trial. Surg Clin North Am. 1981;61:1321-1329.
22. Macdonald JS Adjuvant therapy of gastrointestinal cancer. In: Salmon SE, ed. Adjuvant therapy of cancer. New York: Grune & Stratton; 1987:479-496.
23. Wolmark N., Fisher B., Rockette H.,et al.Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80:30-36.
24. Windle R., Bell PRF, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Cancer. 1987;74: 569-572.
25. Carter SK Large bowel cancer: The current status of treatment. J Natl Cancer Inst. 1976;56:3-10.
26. Moertel CG Large bowel. In: Holland JF, Frei E, eds. Cancer Medicine. Philadelphia: Lea & Fibiger; 1973: 1497-1626.
27. Moertel CG Therapy of advanced gastrointestinal cancer with the nitrosoureas. Cancer Cbemotber. 1973;3-4:27.
28. Macdonald JS, Neefe J. Chemotherapy in the management of gastrointestinal cancer. Abdominal Surg. 1979;21:126-131.
29. Moertel CG Clinical management of advanced gastrointestinal cancer. Cancer. 1975;36:675.
30. Moertel CG Chemotherapy of gastrointestinal cancer. N Engl J Med. 1978;299:1049-1052.
31. Wasserman TH, Comis RL, Goldsmith M.,et al.Tabular analysis of clinical chemotherapy of solid tumors. Cancer Chemother Rep. 1975;6:399.
32. Boice JD, Greene I., Hamilton JM,et al.Leukemia and pre-leukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med. 1983;309:1079-1083.
33. O'Connell MJ, Moertel CG, Kvols LK,et al.Clinical trial of cisplatin and intensive course of 5-fluorouracil for the treatment of advanced colorectal cancer. Am J Clin Oncol. 1986;9:192-195.
34. Schabel FM Jr, Trader MW, Laster WR,et al.Cisdichlorodiammine platinum (II): combination chemotherapy and cross resistance studies with tumors in mice. Cancer Treat Rep. 1979;63:1459-1473.
35. Shimada Y., Yoshino M., Wakui A.,et al.Phase II study of CPT-11: a new camptothecin derivative. Proc Am Soc Clin Oncol. 1991;10:135.
36. Creemers GJ, Lund B., Verwij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev. 1994;20:73-96.
37. Wilke H. CPT-11: from DNA topology to clinical activity. Inpharmacology. 1995; (suppl 1):9-10.
38. Levi F., Machover D., Marty M.,et al.Oxaliplatin (L-OHPR): summary of results in advanced colorectal cancer (ACC) [Abstract]. Eur J Cancer. 1995; 31A(suppl. 5):154.
39. Jackman AL, Jones TR, Calvert HA Thymidilate synthetase inhibitors: experimental and clinical aspects. In: Muggia FM, ed. Experimental and Clinical Progress in Cancer Chemotherapy. Boston: Martinus Nijhoff; 1985:155-210.
40. Diasio RB, Harris BE Clinical pharmacology of 5-fluorouracil. Clin Pbarmacokinet. 1989;16:215-237.
41. Jackman AL, Farrugia DC, Gibson W.,et al.ZD1694 (Tomudex): a new thymidilate synthase inhibitor with activity in colorectal cancer. Eur J Cancer. 1995;31A:1277-1282.
42. Grem JL Current therapeutic strategies to enhance 5-fluorouracil activity. J Infect Chemother. 1992;2: 138-141.
43. Kemeny N., Lokich JJ, Anderson N.,et al.Recent advances in the treatment of advanced colorectal cancer. Cancer. 1993;71:9-18.
44. Grem JL, King SA, O'Dwyer PJ,et al.Biochemistry and clinical activity of N-(phosphonoacetyl)-L-aspartate: a review. Cancer Res. 1988;48:4441-4454.
45. Grem JL, McAtee N., Murphy RF,et al.A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J Clin Oncol. 1991;9:1811-1820.
46. Cadman E., Heimer R., Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: explanation for drug synergism. Science. 1979;205:1135-1137.
47. Rustum YM, Trave F., Zakrzewski SF,et al.Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr. 1987;5:165-170.
48. Petrelli N., Herrera L., Rustum Y.,et al.A prospective randomized trial of 5-fluorouracil vs 5-fluorouracil and high dose leucovorin vs 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5: 1559-1565.
49. Ehrlichman C., Fine S., Wong A.,et al.Randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988; 6:469-475.
50. O'Connell MJ A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. Cancer. 1989;63:1026-1030.
51. Petrelli N., Stablein D., Bruckner H.,et al.A prospective randomized phase III trial of 5-fluorouracil (5-FU) versus 5-FU + high dose leucovorin (LDCF) in patients (PTS) with metastatic colorectal adenocarcinoma. A report of the Gastrointestinal Tumor Study Group. Proc Am Soc Clin Oncol. 1988;7:94.
52. Doroshow JH, Multhauf P., Leong L.,et al.Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol. 1990;8:491-501.
53. Wolmark N., Rockette H., Fisher B.,et al.The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from national surgical adjuvant breast and bowel project protocol C- 03. J Clin Oncol. 1993; 11:1879-1887.
54. Grem JL, Allegra CJ Toxicity of levamisole and 5-fluorouracil in human colon carcinoma cells. J Natl Cancer Inst. 1989;81:1413-1417.
55. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for patients with colon cancer and rectum cancer. Office of Medical Applications of Research. Bethesda, MD: National Institutes of Health; 1990:April 16-18.
56. Kemeny MM Adjuvant hepatic artery chemotherapy. J Infect Chemother. 1992;2:111-114.
57. Taylor I., Machin D., Mullee M.,et al.A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg. 1985;72: 359-362.
58. Wereldsma JCJ, Bruggink Erm, Meijer WS,et al.Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control: results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer. 1990;65:425- 432.
59. Beart RW Jr, Moertel CG, Wieand HS,et al.Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. Arch Surg. 1990;125:897-901.
60. Wolmark N., Rockette H., Wickerham DL,et al.Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of national surgical adjuvant breast and bowel protocol C-02. J Clin Oncol. 1990;8:1466-1475.
61. Piedbois P., Buyse M., Gray M.,et al.Portal vein infusion is an effective adjuvant treatment for patients with colorectal cancer. Proc Am Soc Clin Oncol. 1995;14:192.
62. Kemeny M., Daly J., Reichman B.,et al.Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: a randomized trial. Ann Intern Med. 1987;107:459- 465.
63. Hohn DC, Stagg RJ, Friedman MA,et al.A randomised trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol. 1989;7: 1646-1654.
64. Chang AE, Schneider PD, Sugarbaker PH,et al.A prospective randomized trial of regional vs. systemic continuous 5-FU chemotherapy in the treatment of colorectal metastases. Ann Surg. 1987;206:685-693.
65. Martin JK, O'Connell MJ, Wieand HS,et al.Intraarterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg. 1990;125:1022-1027.
66. Rougier P., Hay JM, Olivier JM,et al.A controlled multicentric trial of intrahepatic artery chemotherapy vs. standard palliative treatment for colorectal liver metastases. Proc Am Soc Clin Oncol. 1990;9:104.
67. Moertel CG Chemotherapy for colorectal cancer. N Engl J Med. 1994;330:1136-1441.
68. Ahlgren JD Protracted infusional schedules of fluorouracil in colorectal cancer versus fluorouracil with modulators: differences and similarities. J Infect Chemother. 1992;2:128-137.
69. Lokich JJ, Ahlgren JD, Gullo JJ,et al.A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol. 1989;7:1419-1426.
70. Weinerman B., Shah A., Fields A.,et al.A randomized trial of continuous systemic infusion versus bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol. 1991; 10:143.
71. Clarke SJ, Jackman AL, Judson IR The history of the development and clinical use of CB 3717 and ICI D1694. Adv Exp Med Biol. 1993;339:277-287.
72. Bird OD, Vaitkus JW, Clarke J. 2-Amino-4-hydroxyquinazolines as inhibitors of thymidilate synthetase. Mol Pbarmacol. 1970;6:573-575.
73. Jackman AL, Gibson W., Brown B.,et al.The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol. 1993;339:265-276.
74. Zalcberg JR, Cunningham D., Van Cutsem E,et al.ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol. 1996; 14: 716-721.
75. Anderson H., Cunningham D., Kerr D.,et al.Mature data from a large randomised trial of 'Tomudex' vs 5-fluorouracil plus folinic acid (Mayo regimen) in advanced colorectal cancer. Abstract submitted to British Oncological Association Meeting, Cardiff, 7-9 July1996.
76. Webb A., Ross P., Cunningham D.,et al.Colorectal cancer- how acceptable to patients is "acceptable" toxicity? [Abstract]. In: Proceedings of the 6tb International Congress on Anticancer Treatment. Paris, 1996:326.
77. De Gramont A, Krulik M., Cady J.,et al.High-dose leucovorin and 5 -fluorouracil bolus and infusion in advanced colorectal cancer. Eur J Clin Oncol. 1988; 24:1499-1503.
78. Cunningham D., Zalcberg JR, Rath U.,et al."Tomudex" (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer. 1995;31A:1945-1954.
79. Kerr D. "Tomudex" (ZD 1694), a new direct and specific thymidylate synthase inhibitor, has resource saving implications in the management of colorectal cancer. Qual Life Res. 1995;4:576.
80. Anonymous. "Tomudex" Data sheet. Zeneca Pharma, August 1995.
81. Davis MR Guidelines for safe handling of cytotoxic drugs in pharmacy departments and hospital wards. Hosp Pharm. 1981;16:17-20.
82. Gregoire RE, Segal R., Hale KM Handling antineoplastic drug admixtures at cancer centers: practices and pharmacist attitudes. Am J Hosp Pharm. 1987; 44:1090-1095.
83. Allwood M, Wright P, eds. The Cytotoxics Handbook, 2nd ed. Oxford: Radcliffe; 1993.
84. Summerhayes M. Cost and pharmacy workload implications of raltitrexed treatment. Inpharmacology. 1996; (suppl 2):10-11.
85. Ross P., Heron J., Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Ann Oncol. Submitted for publication.
86. Valanis BG, Vollmer WM, Labuhn KT,et al.Association of antineoplastic drug handling with acute adverse effects in pharmacy personnel. Am J Hosp Pharm. 1993;50:455- 462.
87. Anonymous. Pharmacist wins cancer case. Aust J Pharm. 1990;71:391.
88. Rodriquez P., Yap CY Abnormal blood results found in pharmacists preparing cytotoxics. Aust J Hosp Pharm. 1991;21:39.